Discover

EDIT
Editas Medicine, Inc.
3.28
2 x 2.50
2 x 4.01
bid
ask
+
0.04
1.23%
2 @ 07:04 AM
3.28 +0.00 (0.00%)
Ytd60.00%
1y45.78%
3.13
day range
3.48
1.66
52 week range
4.54
Open3.22Prev Close3.24Low3.13High3.48Mkt Cap503.35M
Vol2.98MAvg Vol2.34MEPS-1.14P/EN/AForward P/E-0.53
Beta2.01Short Ratio6.70Inst. Own70.94%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0550-d Avg2.90200-d Avg2.681yr Est3.67

EDIT News

Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,

benzinga.com
Editas Medicine Prices $125M Public Offering Of 55.6M Shares And Warrants At $2.25 Each

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
Editas Medicine Launches Public Stock Offering to Raise Capital

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company developing transformative med

benzinga.com
Editas Reports Cholesterol-Lowering Results for Experimental Gene Therapy

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

benzinga.com
Editas Medicine Announces New Preclinical Data Supporting Continued Advancement Of Its In Vivo Devel

The data is being presented this week at the 2026 Annual Meeting of the American Society of Gene and

benzinga.com
Chardan Capital Maintains Buy on Editas Medicine, Raises Price Target to $4

Chardan Capital analyst Geulah Livshits maintains Editas Medicine (NASDAQ:EDIT) with a Buy and ra

benzinga.com
Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.26) per share which beat the analyst

benzinga.com
Editas Medicine To Present New Preclinical Data Demonstrating Progress Of EDIT-401 As Potential Trea

Five abstracts have been accepted for presentation, including one oral presentation and two poster p

benzinga.com
Editas Medicine Says USPTO Upholds PTAB Ruling Favoring Broad Institute In CRISPR Patent Interferenc

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

benzinga.com
Editas Medicine Sees USPTO Reaffirm Broad Institute's CRISPR Patent Priority

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

benzinga.com
Jones Trading Upgrades Editas Medicine to Buy, Announces $8 Price Target

Jones Trading analyst Soumit Roy upgrades Editas Medicine (NASDAQ:EDIT) from Hold to Buy and anno

Editas Medicine Q4 Earnings Assessment
benzinga.com
Editas Medicine Q4 Earnings Assessment

benzinga.com
Editas Medicine Q4 EPS $(0.06) Beats $(0.25) Estimate, Sales $24.741M Beat $5.595M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst

benzinga.com
Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst

benzinga.com
Editas Medicine To Present Data On LDL Cholesterol–Lowering In Vivo Crispr Gene Editing Medicine At

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transf

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
benzinga.com
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a s

benzinga.com
Editas Medicine To Deliver EDIT-401 Oral Presentation At European Society Of Gene And Cell Therapy C

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transfo

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
benzinga.com
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
Earnings Scheduled For May 12, 2025

benzinga.com
Earnings Scheduled For March 5, 2025

benzinga.com
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

benzinga.com
Earnings Scheduled For February 28, 2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a

benzinga.com
Earnings Scheduled For November 3, 2023

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report q

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023

benzinga.com
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company anno

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023

benzinga.com
Earnings Scheduled For August 2, 2023

Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimat

benzinga.com
Earnings Scheduled For May 5, 2023

Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly e

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  Monday's session saw 114 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  On Wednesday, 220 stocks hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  During Tuesday, 95 stocks hit new 52-week lows.

benzinga.com
Earnings Scheduled For February 22, 2023

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  Thursday's session saw 329 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 298 companies achieved new lows for the year.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  Wednesday saw 219 companies set new 52-week lows.

benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022

Upgrades

benzinga.com
Earnings Scheduled For November 2, 2022

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i

benzinga.com
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot

Here's a roundup of top developments in the biotech space over the last 24 hours:

benzinga.com
Earnings Scheduled For August 3, 2022

  Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 951 companies hit new 52-week lows.

benzinga.com
Earnings Scheduled For May 4, 2022

  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday, 849 stocks hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

    On Wednesday, 348 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

    During Tuesday's trading, 505 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

    On Friday, 313 companies hit new 52-week lows.